Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19

NCT04504032 is registered in ClinicalTrials.gov with Gates Medical Research Institute as lead sponsor.

NCT NCT04504032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19
Lead sponsor
Gates Medical Research Institute
Phase
Phase 2
Overall status
Terminated
Start date
September 2, 2020
Completion date
March 29, 2021
Enrollment
497 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19